First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial - PubMed
4 hours ago
- #immunotherapy
- #biomarker discovery
- #colorectal cancer
- First-line Nivolumab plus FOLFOXIRI/Bevacizumab evaluated in RAS/BRAF-mutated colorectal cancer in the phase II NIVACOR trial.
- Objective Response Rate (ORR) was 76.7% with a disease control rate of 97.3%.
- Median progression-free survival (mPFS) was 10.1 months; median overall survival (mOS) not reached.
- 65.8% of patients experienced grade 3 or higher treatment-related adverse events.
- Genomic and transcriptomic profiles linked to treatment response in pMMR/MSS patients identified.
- Alterations in PI3K/AKT, chemokine signaling, and DNA repair pathways correlated with treatment activity.
- Potential synergy between immune checkpoint inhibitors and cytotoxic chemotherapy highlighted.